Literature DB >> 10349545

Current therapy of cutaneous melanoma.

S R Mays1, B R Nelson.   

Abstract

We review the current therapy for cutaneous malignant melanoma. Early surgical resection offers the best likelihood of cure. The initial staging of melanoma patients determines subsequent therapeutic decisions and follow-up care. The prognosis and appropriate therapy for each stage of melanoma are discussed. We review the controversy over lymph node dissection, and recent recommendations for the use of lymphoscintigraphy. Interferon-alpha continues to be the only Food and Drug Administration-approved adjuvant therapy for high-risk patients. In addition, the follow-up care of melanoma patients will be discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349545

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  5 in total

Review 1.  Targeting the RAS pathway in melanoma.

Authors:  Zhenyu Ji; Keith T Flaherty; Hensin Tsao
Journal:  Trends Mol Med       Date:  2011-09-30       Impact factor: 11.951

2.  Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma.

Authors:  G C O'Brien; R A Cahill; D J Bouchier-Hayes; H P Redmond
Journal:  Ir J Med Sci       Date:  2006 Jan-Mar       Impact factor: 1.568

3.  Massive bilateral adrenal gland metastases from melanoma diagnosed by F18-FDG-PET/CT.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Carlo Rodella; Thomas Werner; Raffaele Giubbini; Abass Alavi
Journal:  Jpn J Radiol       Date:  2009-11-27       Impact factor: 2.374

4.  Malignant melanoma in a black child: predisposing precursors and management.

Authors:  Olanrewaju T Adedoyin; Abdul-Wahab B R Johnson; Ayodele I Ojuawo; Enoch A O Afolayan; Kayode A Adeniji
Journal:  J Natl Med Assoc       Date:  2004-10       Impact factor: 1.798

5.  Molecular markers of tumor progression in melanoma.

Authors:  Joshua Rother; Dan Jones
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.